Pfizer Inc. (NYSE:PFE) has agreed to share a portion of the incremental net revenue it generates from higher drug prices overseas with the U.S. Department of Health and Human Services (HHS), according to newly released documents covering its Most Favored Nation (MFN) pricing agreement. The provision applies to medicines already on the market and runs from January 1, 2026, through January 20, 2029, although the revenue-sharing percentage and specific drugs covered remain redacted. HHS says the money will be used to lower costs for U.S. patients and taxpayers.
The arrangement builds on Pfizer’s September 2025 agreement with the U.S. government, under which the company agreed to make certain U.S. drug prices more comparable with those in other developed countries in exchange for a three-year exemption from certain Section 232 tariffs, subject to additional U.S. manufacturing investment. Pfizer generated $62.6 billion of revenue in 2025, with 41% coming from international operations, making overseas pricing an important part of its revenue base.
Also read: Pfizer (PFE) Targets Air Traffic Fees Over Unpaid Vaccines. Can it Turn a Court Win Into Cash?
Pfizer’s Global Business Offers a Cushion Against U.S. Pricing Pressure
The main potential benefit is that Pfizer Inc. could offset some of the pressure from lower U.S. prices by securing higher prices in international markets. The company generated $25.5 billion, or 41% of total revenue, internationally in 2025, and international revenue increased 2% that year even as total revenue declined 2%. Several key products are already demonstrating stronger international growth: Vyndaqel international revenue rose 34% to $2.5 billion, while Prevnar international revenue increased 8% to $2.3 billion.
The agreement could also reduce a major downside risk. Pfizer’s 2025 filing warned that tariffs and changing trade policies could materially affect earnings, cash flow and liquidity. The three-year tariff grace period therefore provides greater cost visibility while Pfizer expands U.S. manufacturing. Reuters reported that the original agreement also required Pfizer to align certain Medicaid prices with prices in other developed countries, while shielding the company from the threatened pharmaceutical tariffs.
Revenue Sharing Could Limit Pfizer’s International Pricing Gains
The revenue-sharing provision means Pfizer Inc. will not retain all of the incremental benefit from raising prices abroad. That is particularly relevant because the company is already facing substantial pricing pressure across international markets. Pfizer’s 2025 filing notes that international reference pricing, government procurement systems, and price controls can constrain prices globally, while Eliquis experienced price erosion in some international markets. The lack of disclosure around the HHS revenue share also makes it difficult to determine how much of any overseas pricing improvement would ultimately reach Pfizer’s earnings and cash flow.
There is also a competitive and regulatory risk if governments resist higher prices. Pfizer Inc.’s 2025 revenue already fell 2% to $62.6 billion, while several mature products face declining sales or pricing pressure. Comirnaty revenue fell 20% operationally to $4.4 billion, Paxlovid fell 59% to $2.4 billion, and Xeljanz declined 7% to $1.1 billion. A strategy that depends on raising overseas prices could become harder to execute if foreign governments respond with tighter reimbursement controls or if competitors maintain lower prices.
Conclusion
The agreement creates a potential avenue for Pfizer to recover some of the economics sacrificed through lower U.S. drug prices, while the tariff protection provides meaningful cost and policy visibility. Its value is nevertheless constrained by the requirement to share incremental overseas revenue with HHS and by the difficulty of raising prices in markets where governments already use international reference pricing.
With 41% of Pfizer’s revenue coming internationally, successful execution could support revenue and cash flow, but the undisclosed revenue-sharing rate makes the financial benefit impossible to quantify precisely at this stage.
READ NEXT: A New Wave of Senior Patients Could Extend Lilly’s GLP-1 Growth Story and Lilly’s Oral GLP-1 Push Gains Momentum. Can Foundayo Become its Next Growth Engine?
This article is originally published at Insider Monkey.
